Literature DB >> 23348756

Response to desmopressin is strongly dependent on F8 gene mutation type in mild and moderate haemophilia A.

Sara C M Stoof1, Yvonne V Sanders, Fred Petrij, Marjon H Cnossen, Moniek P M de Maat, Frank W G Leebeek, Marieke J H A Kruip.   

Abstract

Desmopressin causes two- to six-fold increase of factor VIII (FVIII) in mild or moderate haemophilia A patients. However, responses are variable and little is known whether this is associated with F8 gene mutation. The study objective was to assess the relationship between F8 gene mutation and desmopressin response in haemophilia A patients. Desmopressin response (absolute and relative) was determined in 97 hemophilia A patients. Four amino acid changes (Arg2169His, Pro149Arg, Asn637Ser, and Arg612Cys) and a number of other mutations leading to an aberrant FVIII protein or FVIII deficiency were analysed. Patients with Arg2169His showed significantly lower FVIII levels before and after desmopressin compared to all other mutations (p<0.001). Pro149Arg amino acid change showed significantly lower FVIII levels 1 hour after desmopressin compared to all other mutations (p<0.005). An absolute response with FVIII≥0.50 IU/ml after 1 hour was observed in 41% (9 of 22) of patients with Arg2169His; however, this was not sustainable after 6 hours in any of these subjects. No patients with Pro149Arg mutation (n=6) showed an absolute response with FVIII≥0.50 I U/ml. Patients with other mutations showed significantly more complete and partial responses. Relative responses did not differ between mutations. Our study shows that haemophilia A patients with amino acid change Arg2169His or Pro149Arg have a decreased desmopressin response with regard to FVIII levels as compared to other mutations. Our results indicate that response to desmopressin is dependent on the F8 gene mutation type, despite the fact that multiple factors influence the desmopressin response, even within families.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23348756     DOI: 10.1160/TH12-06-0383

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  4 in total

Review 1.  Molecular and clinical predictors of inhibitor risk and its prevention and treatment in mild hemophilia A.

Authors:  Giancarlo Castaman; Karin Fijnvandraat
Journal:  Blood       Date:  2014-08-18       Impact factor: 22.113

2.  Mutations in intron 1 and intron 22 inversion negative haemophilia A patients from Western India.

Authors:  Preethi S Nair; Shrimati D Shetty; S Chandrakala; Kanjaksha Ghosh
Journal:  PLoS One       Date:  2014-05-20       Impact factor: 3.240

3.  Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: protocol for a multicentre single-armed trial, the DAVID study.

Authors:  Lisette M Schütte; Marjon H Cnossen; Reinier M van Hest; Mariette H E Driessens; Karin Fijnvandraat; Suzanne Polinder; Erik A M Beckers; Michiel Coppens; Jeroen Eikenboom; Britta A P Laros-van Gorkom; Karina Meijer; Laurens Nieuwenhuizen; Evelien P Mauser-Bunschoten; Frank W G Leebeek; Ron A A Mathôt; Marieke J H A Kruip
Journal:  BMJ Open       Date:  2019-04-23       Impact factor: 2.692

4.  Desmopressin for bleeding in non-severe hemophilia A: Suboptimal use in a real-world setting.

Authors:  Anne-Fleur Zwagemaker; Fabienne R Kloosterman; Michiel Coppens; Samantha C Gouw; Sara Boyce; Catherine N Bagot; Erik A M Beckers; Paul Brons; Giancarlo Castaman; Jeroen Eikenboom; Shannon Jackson; Marieke J H A Kruip; Frank W G Leebeek; Karina Meijer; Laurens Nieuwenhuizen; Ingrid Pabinger; Karin Fijnvandraat
Journal:  Res Pract Thromb Haemost       Date:  2022-08-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.